Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors from the central nervous method, conolidine modulates alternate molecular targets. A Science Developments analyze identified that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide ava... https://georgea666coz1.blue-blogs.com/profile